Intellia Therapeutics Inc buy Savour
Start price
24.01.21
/
20%
€63.50
Target price
24.01.22
-
Performance (%)
-15.72%
End price
11.03.21
€53.52
Summary
This prediction ended on 11.03.21 with a price of €53.52. The price of Intellia Therapeutics Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -15.72%. Savour has 20% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intellia Therapeutics Inc | -2.156% | -2.156% | -31.315% | -76.055% |
| iShares Core DAX® | 0.794% | 2.841% | 22.630% | 72.985% |
| iShares Nasdaq 100 | 0.016% | -0.939% | 6.943% | 115.777% |
| iShares Nikkei 225® | 0.309% | -0.648% | 13.619% | 49.561% |
| iShares S&P 500 | 0.181% | -0.442% | 4.692% | 69.577% |
According to Savour what are the pros and cons of Intellia Therapeutics Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by Savour for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Buy Intellia Therapeutics Inc